Clinical trial

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

NCT00070252

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Capecitabine Normalized identity: capecitabineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Laboratory Biomarker Analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Pharmacological Study Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tipifarnib Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-09-01

PhasePHASE1 / PHASE2

Conditions

Adult Solid Neoplasmunresolved

Inflammatory Breast Carcinomaverified · MONDO: inflammatory breast carcinoma

Male Breast Carcinomaverified · MONDO: male breast carcinoma

Stage IIIA Breast Cancerunresolved

Stage IIIB Breast Cancerunresolved

Interventions

CapecitabineDRUG · verified · RxNorm: capecitabine

DocetaxelDRUG · verified · RxNorm: docetaxel

Laboratory Biomarker AnalysisOTHER

Pharmacological StudyOTHER

TipifarnibDRUG

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

St LouisMissouri, United States1 Washington D.C.District of Columbia, United States1 JacksonvilleFlorida, United States1 DetroitMichigan, United States1 RochesterMinnesota, United States1 MilwaukeeWisconsin, United States1 ScottsdaleArizona, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00070252 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.